Cargando…
Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early‐stage luminal breast cancer
AIMS: Phosphohistone H3 (PhH3) has been proposed as a novel proliferation marker in breast cancer. This study compares the interobserver agreement for assessment of the mitotic activity index (MAI), Ki67 expression, and PhH3 in a cohort of oestrogen receptor (ER)‐positive breast cancer patients. MET...
Autores principales: | van Steenhoven, Julia E C, Kuijer, Anne, Kornegoor, Robert, van Leeuwen, Gijs, van Gorp, Joost, van Dalen, Thijs, van Diest, Paul J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539961/ https://www.ncbi.nlm.nih.gov/pubmed/32557844 http://dx.doi.org/10.1111/his.14185 |
Ejemplares similares
-
The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index
por: Tancredi-Cueto, Natalia, et al.
Publicado: (2022) -
Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018) -
Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index
por: Lea, Dordi, et al.
Publicado: (2021) -
Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study
por: van Steenhoven, Julia E.C., et al.
Publicado: (2018) -
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer
por: Klintman, Marie, et al.
Publicado: (2013)